Article Sidebar
Published:
Sep 14, 2024Keywords:
Article Details
The Momona Ethiopian Journal of Science accepts the manuscripts for consideration with the understanding that the manuscript has not been published and is not under consideration for publication elsewhere. Only original articles will be considered for publication if they have been published previously as abstracts, but not if they have been published previously as extended abstract (>1000 words). This applies to both electronic and print versions of the journal. The authors should assign copyright ownership to the Editorial Office of MEJS in the event that the manuscript is accepted for publication in the Momona Ethiopian Journal of Science. All accepted manuscripts must be accompanied by a copyright statement signed by all authors. A copy of the copyright form will be supplied along with the final reviewed version of the manuscript that is sent for final proof- reading. Authors may make multiple copies of the form if necessary and send to the Editorial Office with author’s signature(s) even individually.
All articles published by Momona Ethiopian Journal of Science (MEJS) are Open Access under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0). Under this license, authors retain ownership of the copyright for their content, and anyone can copy, distribute, or reuse articles as long as the author and original source are properly cited. In all these cases for re-use, the authors will be given proper credit to the original publication in MEJS.
Main Article Content
An in silico Drug Repurposing Study to Inhibit the Spike Protein of SARS-CoV2
Reza Mohammadhassan
Abstract
SARS-CoV2 has caused the recent mortal pandemic known as COVID-19. The drug repurposing approach can be employed to find the potential drugs capable of binding SARS-CoV2 structural and nonstructural proteins. The present study aimed to repurpose some common FAD-approved antiviral and non-antiviral drugs computationally for SARS-CoV2 treatment. In the in silico study, 89 FDA-approved drugs and Remdesivir, as the control, were analyzed by molecular docking to inhibit the SARS-CoV2 spike (S) protein as the key player in virus-cell binding. First, the Uniport website was used to find receptor and ganglioside binding domains (RBD and GBD, respectively) of the S protein as the target. The structure of the target was downloaded from RCSB, and 'the ligands' structures were downloaded from PubChem. All structures were refined using SPDV and PyRx software. AutoDock Vina was employed for the docking process. The result showed that 8 drugs, including Ledipasvir, Montelukast, Domperidone, Aprepitant, Folic acid, Losartan, Ticagrelor, and Rivaroxaban, can bind S protein and then inhibit the protein function. In addition, Ledipasvir, Montelukast, and Domperidone can bind GBD of the S protein with higher binding energy (-8.2, -8, -7.9 kcal/mol, respectively). On the other hand, higher RBD binding energy was calculated for Ticagrelor (-6.9 kcal/mol), Folic acid, Montelukast, and Domperidone (-6.5 kcal/mol). Generally, the ligands could inhibit GBD more than RBD. According to the binding energy to S protein and low side effects of the studied medications, Ledipasvir and Losartan can be introduced as the most effective candidates for repurposed drugs. Also, Gly496 and Asn137 are the most engaged amino acids in the ligand-receptor interaction from RBD and GBD, respectively.
